Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FOR 46

Drug Profile

FOR 46

Alternative Names: Anti-CD46 antibody drug conjugate - Fortis Therapeutics; FOR-46

Latest Information Update: 27 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fortis Therapeutics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma; Prostate cancer

Most Recent Events

  • 03 Apr 2019 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT03650491)
  • 04 Feb 2019 Phase-I clinical trials in Prostate cancer (Hormone refractory, Metastatic disease) in USA (IV) (NCT03575819)
  • 06 Nov 2018 Fortis Therapeutics plans a phase I trial for Multiple myeloma (Second line therapy or greater) (IV) in early 2019 (IV) (NCT03650491)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top